<DOC>
	<DOCNO>NCT00852137</DOCNO>
	<brief_summary>This Phase II study design evaluate pharmacokinetics PEP005 ( ingenol mebutate ) Gel , 0.05 % apply maximal use set dorsal aspect forearm patient actinic keratoses</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetics PEP005 ( Ingenol Mebutate ) Gel , 0.05 % , When Applied Maximal Use Setting Dorsal Aspect Forearm Patients With Actinic Keratosis</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<criteria>Male female ; Multiple actinic keratosis ( AK ) lesions 100 cm^2 area skin locate dorsal aspect one forearm . Cosmetic therapeutic procedure : within 2 week within 2 cm select treatment area ( ) ; Treatment immunomodulators , interferon/interferon inducer systemic medication suppress immune system : within 4 week ; Treatment 5FU , imiquimod , diclofenac , photodynamic therapy : within 8 week within 2 cm select treatment area ( ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Peplin</keyword>
	<keyword>PEP005</keyword>
	<keyword>Actinic Keratosis</keyword>
</DOC>